Platform
APPROACH
The right macrophage target, in the right patient population, for the right indication.
Macrophages are increasingly recognized as key drivers of disease across a broad range of therapeutic areas, including oncology, fibrosis, cardiometabolic disease, inflammation, and neurodegeneration. Our Macrophage Fingerprinting Platform leverages large-scale, patient-derived single-cell transcriptomic datasets and a proprietary computational framework to identify disease-driving macrophage populations directly in human disease tissue. By resolving macrophage heterogeneity at single-cell resolution, the platform defines functionally distinct molecular fingerprints that distinguish pathogenic macrophage subsets from protective populations and reveal the biological pathways underlying disease progression.
Unlike conventional approaches that treat macrophages as a single cell type, the platform enables precise characterization of the macrophage populations that are most strongly associated with disease severity, progression, and clinical outcome. This provides a powerful foundation for identifying therapeutically actionable targets with direct human disease relevance.
Target identification
Discover novel targets enriched in disease-promoting macrophage populations.
Disease link validation
Establish robust human evidence linking targets and pathways to disease biology.
Indication prioritization
Identify disease settings with the strongest biological rationale for intervention.
Biomarker discovery
Define biomarkers to identify patient populations most likely to benefit from treatment.